Last reviewed · How we verify
Adjunct to incisional glaucoma surgery — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Mitozytrex | MITOMYCIN | Kyowa Kirin Co., Ltd. | Alkylating Drug [EPC] | Indoleamine 2,3-dioxygenase 1 | 1981-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Kyowa Kirin Co., Ltd. · 1 drug in Adjunct to incisional glaucoma surgery
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Adjunct to incisional glaucoma surgery:
- Adjunct to incisional glaucoma surgery treatment updates — RSS
- Adjunct to incisional glaucoma surgery treatment updates — Atom
- Adjunct to incisional glaucoma surgery treatment updates — JSON
Cite this brief
Drug Landscape (2026). Adjunct to incisional glaucoma surgery — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/adjunct-to-incisional-glaucoma-surgery. Accessed 2026-06-10.
Related
- Adjunct to incisional glaucoma surgery full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing